Kura Oncology (NASDAQ:KURA) Reaches New 1-Year Low – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA) shares hit a new 52-week low on Tuesday . The company traded as low as $8.34 and last traded at $8.56, with a volume of 96391 shares changing hands. The stock had previously closed at $8.51.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, November 21st. UBS Group initiated coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and lowered their target price for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Stock Down 4.8 %

The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a 50-day moving average of $12.11 and a 200 day moving average of $17.08. The stock has a market capitalization of $605.00 million, a price-to-earnings ratio of -3.30 and a beta of 0.81.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in Kura Oncology during the third quarter worth $25,000. The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the period. JPMorgan Chase & Co. lifted its stake in Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. Finally, Bellevue Group AG grew its holdings in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.